Huntington's disease (HD) is an autosomal-dominant degenerative disease caused by a cytosine-adenine-guanine trinucleotide expansion in the Huntingtin (htt) gene. The most vulnerable brain areas to mutant HTT-evoked toxicity are the striatum and cortex. In spite of the extensive efforts that have been devoted to the characterization of HD pathogenesis, no disease-modifying therapy for HD is currently available. The A2A adenosine receptor (A2AR) is widely distributed in the brain, with the highest level observed in the striatum. We previously reported that stimulation of the A2AR triggers an anti-apoptotic effect in a rat neuron-like cell line (PC12). Using a transgenic mouse model (R6/2) of HD, we demonstrated that A2AR-selective agonists effectively ameliorate several major symptoms of HD. In the present study, we show that human iPSCs can be successfully induced to differentiate into DARPP32-positive, GABAergic neurons which express the A2AR in a similar manner to striatal medium spiny neurons. When compared with those derived from control subjects (CON-iPSCs), these HD-iPSC-derived neurons exhibited a higher DNA damage response, based on the observed expression of γH2AX and elevated oxidative stress. This is a critical observation, because oxidative damage and abnormal DNA damage/repair have been reported in HD patients. Most importantly, stimulation of the A2AR using selective agonists reduced DNA damage and oxidative stress-induced apoptosis in HD-iPSC-derived neurons through a cAMP/PKA-dependent pathway. These findings support our hypothesis that human neurons derived from diseased iPSCs might serve as an important platform to investigate the beneficial effects and underlying mechanisms of A2AR drugs.

The fresh rhizome of Zingiber zerumbet (L.) Roscoe ex Smith (Zingiberaceae) is widely used as a folk medicine in Taiwan. In this study, the fresh rhizome was extracted with 95 % EtOH and partitioned with diethyl ether. The antitumor effects of the diethyl ether extract were measured in cultured P-388D (1) cells and in an animal model of P-388D (1)-bearing CDF (1) mice. The results indicated that the extract could induce DNA fragmentation in P-388D (1) cells in vitro, and significantly prolong the life of P-388D (1)-bearing CDF (1) mice (ILS% = 127.8) at a dosage of 5 mg/kg body weight. After column chromatography combined with an MTT cytotoxicity bioassay, zerumbone, a cyclic sesquiterpene was isolated from the diethyl ether extract. Zerumbone inhibited the growth of P-388D (1) cells, induced DNA fragmentation in culture, and significantly prolonged the life of P-388D (1)-bearing CDF (1) mice (ILS% = 120.5) at a dosage of 2 mg/kg. Furthermore, zerumbone inhibited the growth of a human leukemia cell line, HL-60 cells, in a time- and concentration-dependent manner, with IC (50) values of 22.29, 9.12, and 2.27 microg/mL for 6, 12, and 18 h, respectively. The cell cycle of HL-60 cells was observed after treatment with zerumbone, which induced G (2)/M cell cycle arrest in HL-60 cells in a time- and concentration-dependent manner, and decreased the cyclin B1/cdk 1 protein level. These results suggest that zerumbone is an active principal of Z. zerumbet and is potentially a lead compound for the development of anticancer drugs.

No abstract

The fresh rhizome of Zingiber zerumbet Smith (Zingiberaceae) is used as a food flavoring and also serves as a folk medicine as an antipyretic and for analgesics in Taiwan. Zerumbone, a monocyclic sesquiterpene was isolated from the rhizome of Z. zerumbet and is the major active compound. In this study, the anti-inflammatory and antinociceptive effects of zerumbone on arthritis were explored using in vitro and in vivo models. Results showed that zerumbone inhibited inducible nitric oxide (NO) synthase (iNOS), cyclooxygenase (COX)-2 expressions, and NO and prostaglandin E2 (PGE2) production, but induced heme oxygenase (HO)-1 expression in a dose-dependent manner in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. When zerumbone was co-treated with an HO-1 inhibitor (tin protoporphyrin (SnPP)), the NO inhibitory effects of zerumbone were recovered. The above results suggest that zerumbone inhibited iNOS and COX-2 through induction of the HO-1 pathway. Moreover, matrix metalloproteinase (MMP)-13 and COX-2 expressions of interleukin (IL)-1β-stimulated primary rat chondrocytes were inhibited by zerumbone. In an in vivo assay, an acetic acid-induced writhing response in mice was significantly reduced by treatment with zerumbone. Furthermore, zerumbone reduced paw edema and the pain response in a mono-iodoacetate (MIA)-induced rat osteoarthritis model. Therefore, we suggest that zerumbone possesses anti-inflammatory and antinociceptive effects which indicate zerumbone could be a potential candidate for osteoarthritis treatment.